Health and Healthcare
Keytruda, COVID-19 Hopes Prompt Merck Earnings Beat, Rosy Outlook
Published:
When Merck & Co. (NYSE: MRK) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37 and $10.9 billion in revenue. That compared with consensus estimates of $1.04 in EPS and $10.39 billion in revenue. The same period of last year reportedly had $1.30 in EPS and $11.76 billion in revenue.
Merck has a few irons in the COVID-19 fire, and it is accelerating two vaccine development efforts and a novel antiviral candidate. The company has a collaboration with the International AIDS Vaccine Initiative for developing a vaccine, and it acquired Themis, which has a vaccine candidate as well. Separately, Merck has a collaboration with Ridgeback Bio for a COVID-19 antiviral treatment.
In terms of the numbers, worldwide sales decreased by 8%, or 5% excluding foreign exchange. This was largely driven by Keytruda sales increasing 29% year over year to $3.4 billion.
Animal Health sales totaled $1.1 billion for the second quarter, a decrease of 2% compared with the second quarter of last year. Excluding the unfavorable effect from foreign exchange, Animal Health sales grew 3%. Performance in livestock products reflects lower demand driven by reduced protein and milk demand due to restaurant and school closures resulting from the COVID-19 pandemic.
Looking ahead to the 2020 full year, Merck expects to see earnings of $5.63 to $5.78 per share and revenue between $47.2 billion and $48.7 billion. Consensus estimates call for $5.31 in EPS and $47.33 billion in revenue for 2019.
Management noted that it remains confident that Merck will drive strong long-term growth based on underlying demand for its unique portfolio of innovative medicines, vaccines and animal health products.
Merck stock traded up about 1% at $80.11 on Friday, in a 52-week range of $65.25 to $92.64. The consensus price target is $93.00.
24/7 Wall St.Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
